T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Self-citationKalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Self-citationAppio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
RECIST 1.1—Update and clarification: From the RECIST committee
Schwartz, L. H., Litière, S., de Vries, E., Ford, R., Gwyther, S., Mandrekar, S., Shankar, L., Bogaerts, J., Chen, A., Dancey, J., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.03.081 · Cited by 1,906
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,382
Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Fraietta, J. A., Nobles, C. L., Sammons, M. A., Lundh, S., Carty, S. A., Reich, T. J., Cogdill, A. P., Morrissette, J. J. D., DeNizio, J. E., Reddy, S., et al. (2018) · Nature · doi:10.1038/s41586-018-0178-z · Cited by 862
Self-citationRuella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659 · cited 1×
“The CAR transgene was inadvertently introduced during CART-19 manufacturing 19 .”
Self-citationDecade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
Scholler, J., Brady, T. L., Binder-Scholl, G., Hwang, W.-T., Plesa, G., Hege, K. M., Vogel, A. N., Kalos, M., Riley, J. L., Deeks, S. G., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003761 · Cited by 652
Self-citationSecond Cancer Risk Up to 40 Years after Treatment for Hodgkin’s Lymphoma
Schaapveld, M., Aleman, B. M. P., van Eggermond, A. M., Janus, C. P. M., Krol, A. D. G., van der Maazen, R. W. M., Roesink, J., Raemaekers, J. M. M., de Boer, J. P., Zijlstra, J. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1505949 · Cited by 637
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Cordeiro, A., Bezerra, E. D., Hirayama, A. V., Hill, J. A., Wu, Q. V., Voutsinas, J., Sorror, M. L., Turtle, C. J., Maloney, D. G., & Bar, M. (2020) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2019.08.003 · Cited by 364
Mueller, K. T., Maude, S. L., Porter, D. L., Frey, N., Wood, P., Han, X., Waldron, E., Chakraborty, A., Awasthi, R., Levine, B. L., et al. (2017) · Blood · doi:10.1182/blood-2017-06-786129 · Cited by 362
Self-citationFive-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy
Chong, E. A., Ruella, M., & Schuster, S. J. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2030164 · Cited by 339
Self-citationLong-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy
Cappell, K. M., Sherry, R. M., Yang, J. C., Goff, S. L., Vanasse, D. A., McIntyre, L., Rosenberg, S. A., & Kochenderfer, J. N. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01467 · Cited by 311
Dunleavy, K., Fanale, M. A., Abramson, J. S., Noy, A., Caimi, P. F., Pittaluga, S., Parekh, S., Lacasce, A., Hayslip, J. W., Jagadeesh, D., et al. (2018) · The Lancet Haematology · doi:10.1016/s2352-3026(18)30177-7 · Cited by 230
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226 · cited 2×
“Other than in the cases treated with the piggy-Bac transposon-engineered CAR T cells 20 , none of the previously discussed SPMs was directly caused by CAR transduction; however, a case of CAR + TCL occurring after infusion of the BCMA-directed CAR T (CART-BCMA) ciltacabtagene autoleucel…”
Second Cancers Among Long-term Survivors of Non-Hodgkin's Lymphoma
Travis, L. B., Curtis, R. E., Glimelius, B., Holowaty, E., Leeuwen, F. E. V., Lynch, C. F., Adami, J., Gospodarowicz, M., Wacholder, S., Inskip, P., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.23.1932 · Cited by 222
Unanswered questions following reports of secondary malignancies after CAR-T cell therapy
Levine, B. L., Pasquini, M. C., Connolly, J. E., Porter, D. L., Gustafson, M. P., Boelens, J. J., Horwitz, E. M., Grupp, S. A., Maus, M. V., Locke, F. L., et al. (2024) · Nature Medicine · doi:10.1038/s41591-023-02767-w · Cited by 201
Self-citationBishop, D. C., Clancy, L. E., Simms, R., Burgess, J., Mathew, G., Moezzi, L., Street, J. A., Sutrave, G., Atkins, E., McGuire, H. M., et al. (2021) · Blood · doi:10.1182/blood.2021010813 · Cited by 177 · cited 1×
“In both cases, the post-CAR T TCL progressed and resulted in the death of one of the patients, whereas the other patient successfully received an allogeneic transplant 20,21 .”
Shah, N. N., Qin, H., Yates, B., Su, L., Shalabi, H., Raffeld, M., Ahlman, M. A., Stetler-Stevenson, M., Yuan, C., Guo, S., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000219 · Cited by 165
Zhao, W., Wang, B., Chen, L., Fu, W., Xu, J., Liu, J., Jin, S., Chen, Y., Cao, X.-M., Yang, Y., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01301-8 · Cited by 152
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy
Miller, P. G., Sperling, A. S., Brea, E. J., Leick, M. B., Fell, G. G., Jan, M., Gohil, S. H., Tai, Y.-T., Munshi, N. C., Wu, C. J., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004554 · Cited by 131
Review of risk factors of secondary cancers among cancer survivors
Goldschmidt, C. D., & de Vathaire, F. (2018) · British Journal of Radiology · doi:10.1259/bjr.20180390 · Cited by 130
Second malignancies after multiple myeloma: from 1960s to 2010s
Thomas, A., Mailankody, S., Korde, N., Kristinsson, S. Y., Turesson, I., & Landgren, O. (2012) · Blood · doi:10.1182/blood-2011-12-381426 · Cited by 127
Ghilardi, G., Chong, E. A., Svoboda, J., Wohlfarth, P., Nasta, S. D., Williamson, S., Landsburg, J. D., Gerson, J. N., Barta, S. K., Pajarillo, R., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.521 · Cited by 107
Self-citationSacchi, S., Marcheselli, L., Bari, A., Marcheselli, R., Pozzi, S., Luminari, S., Lombardo, M., Buda, G., Lazzaro, A., Gobbi, P. G., et al. (2008) · Haematologica · doi:10.3324/haematol.12120 · Cited by 104
Teipel, R., Kroschinsky, F., Krämer, M., Kretschmann, T., Egger‐Heidrich, K., Kruger, T. E., Ruhnke, L., Herold, S., Stasik, S., Sockel, K., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021005747 · Cited by 72
Steffin, D., Muhsen, I. N., Hill, L. C., Ramos, C. A., Ahmed, N. M., Hegde, M. G., Wang, T., Wu, M.-F., Gottschalk, S. M., Whittle, S. B., et al. (2022) · Blood · doi:10.1182/blood.2022015728 · Cited by 56
The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma
Chihara, D., Dores, G. M., Flowers, C. R., & Morton, L. M. (2021) · Blood · doi:10.1182/blood.2020010497 · Cited by 52
T-cell lymphoma secondary to checkpoint inhibitor therapy
Anand, K., Ensor, J., Pingali, S. R., Hwu, P., Duvic, M. A., Chiang, S. B., Miranda, R. N., Zu, Y., & Iyer, S. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000104 · Cited by 47
Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota, V., Kerschbaum, J. F., Penack, O., Stein, C. M., Arends, C. M., Koenecke, C., Strzelecka, P. M., Kloos, A., Wiegand, L., Lasch, A., et al. (2023) · HemaSphere · doi:10.1097/hs9.0000000000000957 · Cited by 46
A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor–positive cells
Ruella, M., Barrett, D. M., Shestova, O. E., Perazzelli, J., Posey, A. D., Hong, S. J., Kozlowski, M. S., Lacey, S. F., Melenhorst, J. J., June, C. H., et al. (2019) · Blood · doi:10.1182/blood.2019001859 · Cited by 38
Self-citationRagon, B. K., Shah, M. V., D’Souza, A., Estrada‐Merly, N., Gowda, L., George, G., Lima, M. J. G. D., Hashmi, S. K., Kharfan‐Dabaja, M. A., Majhail, N. S., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009138 · Cited by 38
Mature T-cell Lymphomagenesis Induced by Retroviral Insertional Activation of Janus Kinase 1
Heinrich, T., Rengstl, B., Muik, A., Petkova, M. V., Schmid, F., Wistinghausen, R., Warner, K., Crispatzu, G., Hansmann, M., Herling, M., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.67 · Cited by 37
The regulation of PBXs and their emerging role in cancer
Liu, Y., Ao, X., Zhou, X., Du, C., & Kuang, S. (2022) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17196 · Cited by 37
Landsburg, D. J., Morrissette, J. J. D., Nasta, S. D., Barta, S. K., Schuster, S. J., Svoboda, J., Chong, E. A., & Bagg, A. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011384 · Cited by 36
Self-citationAnswering the “Doctor, can CAR-T therapy cause cancer?” question in clinic
Banerjee, R. K., Poh, C., Hirayama, A. V. V., Gauthier, J., Cassaday, R. D., Shadman, M. S., Cowan, A. J., Till, B. G., Green, D. J., Kiem, H., et al. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012336 · Cited by 23
Martelin, E., Volin, L., Itälä‐Remes, M., Niittyvuopio, R., Lindström, V., Heiskanen, J., Ruutu, T., & Nihtinen, A. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0290-6 · Cited by 12
Aisner, D. L., Gocke, C. D., Jones, D. M., Limson, M., Morrissette, J. J. D., & Segal, J. P. (2023) · Academic Pathology · doi:10.1016/j.acpath.2023.100090 · Cited by 8
Self-citationComposite follicular lymphoma and classic Hodgkin lymphoma
(2021) · doi:10.4132/jptm.2021.10.09 · Cited by 7
Cited by
CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review
Brudno, J. N., Maus, M. V., & Hinrichs, C. S. (2024) · JAMA · doi:10.1001/jama.2024.19462 · Cited by 359
In vivo CAR T cell generation to treat cancer and autoimmune disease
Hunter, T. L., Bao, Y., Zhang, Y., Matsuda, D., Riener, R., Wang, A., Li, J. J., Soldevila, F., Chu, D. S. H., Nguyen, D. P., et al. (2025) · Science · doi:10.1126/science.ads8473 · Cited by 330
Self-citationCurrent understanding and management of CAR T cell-associated toxicities
Brudno, J. N., & Kochenderfer, J. N. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00903-0 · Cited by 305
A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
Cordas dos Santos, D. M., Tix, T., Shouval, R., Gafter-Gvili, A., Alberge, J.-B., Cliff, E. R. S., Theurich, S., von Bergwelt-Baildon, M., Ghobrial, I. M., Subklewe, M., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03084-6 · Cited by 287
The molecular basis of the anticancer effect of statins
Buccioli, G., Testa, C., Jacchetti, E., Pinoli, P., Carelli, S., Ceri, S., & Raimondi, M. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-71240-6 · Cited by 13
Metadata
- Authors
- Ghilardi, G., Fraietta, J. A., Gerson, J. N., Van Deerlin, V. M., Morrissette, J. J. D., Caponetti, G. C., Paruzzo, L., Harris, J. C., Chong, E. A., Susanibar Adaniya, S. P., Svoboda, J., Nasta, S. D., Ugwuanyi, O. H., Landsburg, D. J., Fardella, E., Waxman, A. J., Chong, E. R., Patel, V., Pajarillo, R., Kulikovskaya, I., Lieberman, D. B., Cohen, A. D., Levine, B. L., Stadtmauer, E. A., Frey, N. V., Vogl, D. T., Hexner, E. O., Barta, S. K., Porter, D. L., Garfall, A. L., Schuster, S. J., June, C. H., & Ruella, M.
- Venue
- Nature Medicine
- Published
- 2024-01-24
- Volume
- 30
- Issue
- 4
- Pages
- 984-989
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W4391211463
- Cited by
- 270
- References
- 41
- FWCI
- 41.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.